PUBLISHER: The Business Research Company | PRODUCT CODE: 1608809
PUBLISHER: The Business Research Company | PRODUCT CODE: 1608809
A positron emission tomography (PET) radiotracer is a radioactive substance used in PET imaging. This radiotracer is administered to a patient via injection, where it binds to specific biological targets, enabling the PET scanner to visualize metabolic activity and diagnose conditions such as cancer or neurological disorders.
The primary types of PET radiotracers include F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), and others. F-18 (Fluorodeoxyglucose 18) radiotracers are radioactive glucose analogs utilized in PET imaging to evaluate metabolic activity in tissues, particularly for cancer detection. These radiotracers are applied across various medical fields, including oncology, cardiology, gastrointestinal disorders, endocrine issues, and neurology. They are used by end-users such as hospitals and diagnostic centers, among others.
The positron emission tomography (PET) radiotracer market research report is one of a series of new reports from The Business Research Company that provides positron emission tomography (PET) radiotracer market statistics, including the positron emission tomography (PET) radiotracer industry's global market size, regional shares, competitors with a positron emission tomography (PET) radiotracer market share, detailed positron emission tomography (PET) radiotracer market segments, market trends and opportunities, and any further data you may need to thrive in the positron emission tomography (PET) radiotracer industry. This positron emission tomography (PET) radiotracer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The positron emission tomography (PET) radiotracer market size has grown strongly in recent years. It will grow from $2.15 billion in 2023 to $2.35 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to the rising prevalence of infectious diseases, greater awareness and accessibility of healthcare, the emergence of novel radiotracers, the increasing incidence of cancer, and a heightened focus on preventive medicine.
The positron emission tomography (PET) radiotracer market size is expected to see strong growth in the next few years. It will grow to $3.33 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The anticipated growth during the forecast period can be attributed to the expansion of applications, regulatory approvals, growth in emerging markets, an increasing geriatric population, and the rising adoption of PET radio scanners. Key trends during this period include the development of micro-PET technology, integration with wearable technology, expansion of theranostics, advancements in nano-radiotracers, and the use of blockchain for data security.
The anticipated rise in infectious diseases is projected to drive the growth of the positron emission tomography (PET) radiotracer market in the coming years. Infectious diseases are illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, or parasites. Factors contributing to the increased prevalence of these diseases include climate change, urbanization, globalization, antibiotic resistance, and shifts in human behavior, all of which facilitate the spread of pathogens. PET radiotracers play a crucial role in managing infectious diseases by visualizing metabolic activity and inflammation, which aids in the detection of infections, assessment of treatment responses, and differentiation between infectious and non-infectious conditions, ultimately leading to improved patient outcomes. For example, in February 2024, a report from the UK Health Security Agency, a government agency in the UK, indicated that tuberculosis (TB) cases in England rose by 10.7% in 2023, with 4,850 cases reported compared to 4,380 in 2022. Hence, the growing prevalence of infectious diseases is driving demand for the PET radiotracer market.
Leading companies in the PET radiotracer market are concentrating on developing advanced diagnostic solutions, such as PET imaging agents that improve cancer detection and enhance patient outcomes. A PET imaging agent is a radioactive substance utilized to visualize and measure biological processes in the body during PET scans. For instance, in March 2023, IsoLogic Innovative Radiopharmaceuticals, a Canadian radiopharmaceutical firm, launched Illuccix, also known as the Ga-68 Gozetotide Preparation Kit (PSMA-11), in Canada as a prostate cancer imaging agent aimed at detecting metastatic prostate cancer. This tool is crucial for physicians in identifying metastatic disease and making informed patient management decisions. It is indicated for patients suspected of metastasis who are candidates for initial definitive therapy, as well as for those with suspected recurrence indicated by elevated serum prostate-specific antigen (PSA) levels.
In February 2023, Lantheus Holdings Inc., a U.S.-based developer of diagnostic products, acquired Cerveau Technologies for an undisclosed sum. This acquisition is intended to enhance Lantheus Holdings' imaging pipeline, particularly for Alzheimer's disease diagnostics, by integrating Cerveau's MK-6240, a second-generation PET imaging agent that targets tau tangles in the brain. Cerveau Technologies Inc. is a U.S.-based provider of information and technology specializing in PET radiotracers.
Major companies operating in the positron emission tomography (PET) radiotracer market are Cardinal Health Inc., AstraZeneca PLC, Eli Lilly and Company, Siemens Healthineers AG, GE Healthcare Technologies Inc., Philips Healthcare, Bracco Imaging S.p.A., Neusoft Medical Systems Co Ltd., Lantheus Holdings Inc., Jubilant Pharma Limited, SOFIE Biosciences (SOFIE), Yantai Dongcheng Pharmaceutical Group Co. Ltd., Nordion Inc., RefleXion Medical Inc., Isologic Innovative Radiopharmaceuticals, ABX Advanced Biochemical Compounds GmbH, IBA Radiopharma Solutions S.A., IXICO PLC, ImaginAb Inc., Radiomedix Inc.
North America was the largest region in the positron emission tomography (PET) radiotracer market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (PET) radiotracer marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the positron emission tomography (PET) radiotracer marker report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The positron emission tomography (PET) radiotracer market consists of sales of FDG (fluorodeoxyglucose), f-dopa (fluorodopa), C-11 methionine, C-11 methionine, F-18 naf (sodium fluoride), and C-11 choline. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Positron Emission Tomography (PET) Radiotracer Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on positron emission tomography (PET) radiotracer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for positron emission tomography (PET) radiotracer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The positron emission tomography (PET) radiotracer market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.